HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals (NASDAQ:INO) in a report published on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Maxim Group set a $12.00 price target on shares of Inovio Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, January 2nd. Citigroup started coverage on shares of Inovio Pharmaceuticals in a report on Friday, October 6th. They issued a buy rating and a $10.00 target price on the stock. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 9th. Royal Bank of Canada started coverage on shares of Inovio Pharmaceuticals in a report on Wednesday, October 18th. They issued an outperform rating and a $11.00 target price on the stock. Finally, BidaskClub lowered shares of Inovio Pharmaceuticals from a hold rating to a sell rating in a report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $19.16.

Inovio Pharmaceuticals (INO) traded up $0.01 on Friday, reaching $4.48. 740,900 shares of the company were exchanged, compared to its average volume of 1,290,000. The firm has a market capitalization of $402.72, a price-to-earnings ratio of -3.80 and a beta of 2.74. Inovio Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). The business had revenue of $2.60 million for the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The business’s revenue was down 79.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. analysts forecast that Inovio Pharmaceuticals will post -1.12 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Belpointe Asset Management LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $150,000. Neuberger Berman Group LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $115,000. Alyeska Investment Group L.P. purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $892,000. Allianz Asset Management GmbH raised its stake in shares of Inovio Pharmaceuticals by 12.4% in the 3rd quarter. Allianz Asset Management GmbH now owns 222,768 shares of the biopharmaceutical company’s stock valued at $1,412,000 after acquiring an additional 24,652 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $117,000. Institutional investors own 32.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/15/inovio-pharmaceuticals-ino-given-a-13-00-price-target-at-hc-wainwright.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Stock Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related stocks with our FREE daily email newsletter.